Maat
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
70 Avenue Tony Garnier, Lyon, Auvergne-R...Phone Number
+33 428291400Website
www.maatpharma.comRevenue
<$5 MillionStock Symbol
MAATIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Maat
MaaT Pharma is a clinical-stage oncology company focused on microbiome restoration therapy using biotherapeutics to treat life-threatening diseases. The company was founded in 2014 and is headquartered in Lyon, France.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Maat your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Maat, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Maat
Funding: Get notified immidiatlly once Maat has new funding data
Product Launch: Get notified when Maat launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Maat had a recent Job posting/layoffs
Check out if Maat is spiking on competitors!
Earning: See what the market has to say on Maat recently announced quarterly report
Check if Maat has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Maat as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Maat is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Maat is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Maat.
Maat financials insights
Gather financial insights about Maat, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Unspecified
$1.3M
Unspecified
$1.1M
2016
Series A
$11.2M
2020
Series B
$29.5M
2025
Share Placement
$14M
Debt
$43.7M
Maat Tech Stack
A closer look at the technologies used by Maat
See more technologies
Most Recent Scoops
Partnership
Maat has entered into an exclusive distribution licensing agreement with UK-based Clinigen, granting Clinigen the rights to distribute Maat's product across all European countries upon commercialization, with Maat supplying the product ex-factory from its facility near Lyon effective January 1, 2026.
Partnership, Pharmaceuticals
Project
Maat is advancing MaaT033, an oral capsule formulation, in the PHOEBUS trial a potential registration study enrolling approximately 390 patients undergoing stem cell transplantation. End of recruitment and public communication are projected for the second half of 2027, with results expected in 2028.
Clinical Operations
Earnings
reported revenues of EUR 4.5 million for fiscal year 2025, representing a 38% increase compared to 2024, driven primarily by its early and compassionate access program.
Earnings, Finance
Pain Point
Maat has received a negative trend opinion from the European Medicines Agency's CHMP regarding its marketing authorization application for MaaT013 in graft-versus-host disease (GvHD), following an oral hearing on May 19, with a formal negative decision expected at the CHMP meeting scheduled for June 22 to 26.
Pharmaceuticals
Earnings
Accounting, Financial Reporting, Business Finance, Finance
Maat News & Media
MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a ...
LYON, France, July 28, 2025--MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in OncologyMaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General MeetingMaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Maat
Sign Up For FreeTo access detailed company insights
MaaT Pharma is a clinical-stage oncology company focused on microbiome restoration therapy using biotherapeutics to treat life-threatening diseases. The company was founded in 2014 and is headquartered in Lyon, France.... Read More
